{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T19:21:39Z","timestamp":1788895299765,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian Journal of Tuberculosis"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.ijtb.2016.01.031","type":"journal-article","created":{"date-parts":[[2016,6,18]],"date-time":"2016-06-18T20:50:41Z","timestamp":1466283041000},"page":"106-114","source":"Crossref","is-referenced-by-count":29,"title":["Frequency of adverse events observed with second-line drugs among patients treated for multidrug-resistant tuberculosis"],"prefix":"10.1016","volume":"63","author":[{"given":"Rajendra","family":"Prasad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giridhar B.","family":"Hosmane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram Awadh Singh","family":"Kushwaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijtb.2016.01.031_bib0165","series-title":"World Health Organization Global Tuberculosis Report 2012. WHO\/HTM\/TB\/2012.6","year":"2012"},{"key":"10.1016\/j.ijtb.2016.01.031_bib0170","first-page":"829","article-title":"Treatment of MDR-TB: evidence and controversies","volume":"10","author":"Caminero","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijtb.2016.01.031_bib0175","first-page":"53","article-title":"Managing MDR-TB","volume":"21","author":"Farmer","year":"2000","journal-title":"J Respir Dis"},{"key":"10.1016\/j.ijtb.2016.01.031_bib0180","series-title":"Tuberculosis: A Comprehensive International Approach","first-page":"447","article-title":"Responding to outbreaks of MDR-TB: introducing DOTS-PLUS","author":"Farmer","year":"2000"},{"key":"10.1016\/j.ijtb.2016.01.031_bib0185","series-title":"WHO\/CDS\/TB\/2000.279","article-title":"World Health Organization Guidelines for establishing DOTS-PLUS pilot projects for the management of MDR-TB","year":"2000"},{"key":"10.1016\/j.ijtb.2016.01.031_bib0190","first-page":"170","article-title":"The treatment of MDR-TB in Turkey","volume":"345","author":"Tahaoglu","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijtb.2016.01.031_bib0195","first-page":"648","article-title":"Occurrence of serious adverse effects in patients receiving community-based therapy for MDR-TB","volume":"5","author":"Furin","year":"2001","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijtb.2016.01.031_bib0200","first-page":"131","article-title":"Adverse events associated with pyrazinamide and levofloxacin in the treatment of MDR-TB","volume":"167","author":"Papastavros","year":"2002","journal-title":"CMAJ"},{"key":"10.1016\/j.ijtb.2016.01.031_bib0205","first-page":"1027","article-title":"Adverse events in the treatment of MDR-TB: results from the DOTS-Plus initiative","volume":"9","author":"Nathanson","year":"2005","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijtb.2016.01.031_bib0210","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0140-6736(05)70196-3","article-title":"Clinical outcome of individualized treatment of MDR-TB in Latvia: a retrospective cohort study","volume":"365","author":"Leimane","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ijtb.2016.01.031_bib0215","first-page":"1373","article-title":"Side effects associated with the treatment of MDR-TB","volume":"9","author":"T\u00f6r\u00fcn","year":"2005","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijtb.2016.01.031_bib0220","first-page":"51","article-title":"A comparative study on the adverse effects of two anti-tuberculosis drugs regimen in initial two-month treatment period","volume":"1","author":"Nahar","year":"2006","journal-title":"Bangladesh J Pharmacol"},{"key":"10.1016\/j.ijtb.2016.01.031_bib0225","first-page":"e352","article-title":"Feasibility and cost-effectiveness of treating MDR-TB: a cohort study in the Philippines","volume":"3","author":"Tupasi","year":"2006","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijtb.2016.01.031_bib0230","first-page":"2.e1126","article-title":"MDR-TB treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR-TB among treatment failures","author":"Cox","year":"2007","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijtb.2016.01.031_bib0235","first-page":"1314","article-title":"Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia","volume":"11","author":"Shin","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijtb.2016.01.031_bib0240","first-page":"1203","article-title":"Tolerability of anti-tuberculosis treatment and HIV sero-status","volume":"11","author":"Lanternier","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijtb.2016.01.031_bib0245","doi-asserted-by":"crossref","first-page":"e7186","DOI":"10.1371\/journal.pone.0007186","article-title":"Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa","volume":"4","author":"Seung","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijtb.2016.01.031_bib0250","first-page":"275","article-title":"Adverse events related to MDR-TB treatment, Latvia, 2000\u20132004","volume":"14","author":"Bloss","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijtb.2016.01.031_bib0255","first-page":"427","article-title":"Adverse drug reactions in MDR-TB","volume":"70","author":"Palmero","year":"2010","journal-title":"Medicina (B Aires)"},{"key":"10.1016\/j.ijtb.2016.01.031_bib0260","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1097\/MJT.0b013e3181c0806d","article-title":"Adverse effects of MDR-TB treatment with a standardized regimen: a report from Iran","volume":"18","author":"Baghaei","year":"2011","journal-title":"Am J Ther"},{"key":"10.1016\/j.ijtb.2016.01.031_bib0265","doi-asserted-by":"crossref","first-page":"961","DOI":"10.5588\/ijtld.11.0574","article-title":"Frequency of adverse reactions to first- and second-line anti-tuberculosis chemotherapy in a Korean cohort","volume":"167","author":"Carroll","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijtb.2016.01.031_bib0270","first-page":"6","article-title":"The burden of adverse events during treatment of drug-resistant tuberculosis in Namibia","volume":"5","author":"Sagwa","year":"2012","journal-title":"South Med Rev"},{"key":"10.1016\/j.ijtb.2016.01.031_bib0275","doi-asserted-by":"crossref","first-page":"e58817","DOI":"10.1371\/journal.pone.0058817","article-title":"Serious treatment related adverse drug reactions amongst anti-retroviral naive MDR-TB patients","volume":"8","author":"Van der Walt","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1016\/j.ijtb.2016.01.031_bib0280","first-page":"976","article-title":"Seven-year DOTS-Plus pilot experience in India: results, constraints and issues","volume":"13","author":"Singla","year":"2009","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijtb.2016.01.031_bib0285","first-page":"529","article-title":"Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India","volume":"133","author":"Joseph","year":"2011","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.ijtb.2016.01.031_bib0290","doi-asserted-by":"crossref","first-page":"e28066","DOI":"10.1371\/journal.pone.0028066","article-title":"Ambulatory MDR-TB treatment outcomes in a cohort of HIV-infected patients in a slum setting in Mumbai, India","volume":"6","author":"Saakidis","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijtb.2016.01.031_bib0295","doi-asserted-by":"crossref","first-page":"e40781","DOI":"10.1371\/journal.pone.0040781","article-title":"Adverse events among HIV\/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India","volume":"7","author":"Isaakidis","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijtb.2016.01.031_bib0300","series-title":"Revised National Tuberculosis Control Programme Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis (PMDT) in India","author":"Ministry of Health and Family Welfare","year":"2010"},{"key":"10.1016\/j.ijtb.2016.01.031_bib0305","series-title":"Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Emergency Update 2008. WHO\/HTM\/TB\/2008.402","author":"World Health Organization","year":"2008"},{"key":"10.1016\/j.ijtb.2016.01.031_bib0310","unstructured":"Serena Koenig Management of Side Effects during MDR-TB Treatment; TB CARE II project, United States Agency for International Development."},{"key":"10.1016\/j.ijtb.2016.01.031_bib0315","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1056\/NEJM199302253280802","article-title":"Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin","volume":"328","author":"Goble","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijtb.2016.01.031_bib0320","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1378\/chest.117.3.744","article-title":"Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with Ofloxacin\/levofloxacin-containing regimens","volume":"117","author":"Yew","year":"2000","journal-title":"Chest"}],"container-title":["Indian Journal of Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570716000329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570716000329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T04:28:24Z","timestamp":1536640104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019570716000329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0019570716000329"],"URL":"https:\/\/doi.org\/10.1016\/j.ijtb.2016.01.031","relation":{},"ISSN":["0019-5707"],"issn-type":[{"value":"0019-5707","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}